Local delivery of angiogenesis-inhibitor minocycline combined with radiotherapy and oral temozolomide chemotherapy in 9L glioma

Journal of Neurosurgery
Hansen BowBetty M Tyler

Abstract

Over the past several years, there has been increasing interest in combining angiogenesis inhibitors with radiotherapy and temozolomide chemotherapy in the treatment of glioblastoma. Although the US FDA approved bevacizumab for the treatment of glioblastoma in 2009, the European Medicines Agency rejected its use due to its questionable impact on patient survival. One factor contributing to the failure of angiogenesis inhibitors to increase overall patient survival may be their inability to cross the blood-brain barrier. Here the authors examined in a 9L glioma model whether intracranial polymer-based delivery of the angiogenesis inhibitor minocycline potentiates the effects of both radiotherapy and temozolomide chemotherapy in increasing median survival. The authors also investigated whether the relative timing of minocycline polymer implantation with respect to radiotherapy affects the efficacy of radiotherapy. Minocycline was incorporated into the biodegradable polymer polyanhydride poly(1,3-bis-[p-carboxyphenoxy propane]-co-[sebacic anhydride]) (CPP:SA) at a ratio of 50:50 by weight. Female Fischer 344 rats were implanted with 9L glioma on Day 0. The minocycline polymer was then implanted on either Day 3 or Day 5 posttumor i...Continue Reading

References

Jan 1, 1992·Cancer Chemotherapy and Pharmacology·E A SotomayorE Frei
Sep 4, 1995·International Journal of Cancer. Journal International Du Cancer·J D WeingartH Brem
Apr 1, 1995·Journal of Neurosurgery·J D WeingartH Brem
Jan 1, 1995·Breast Cancer Research and Treatment·B A TeicherD Goff
Jun 3, 2004·Nature Reviews. Drug Discovery·Maciej S Lesniak, Henry Brem
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
May 23, 2006·Cancer Treatment Reviews·Carsten NiederMichael Molls
Dec 15, 2006·The New England Journal of Medicine·Alan SandlerDavid H Johnson
Jul 24, 2007·Nature Reviews. Neuroscience·Rakesh K JainTracy T Batchelor
Sep 11, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jens Overgaard
Oct 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James J VredenburghHenry S Friedman
Dec 3, 2008·Journal of Neurosurgery·Matthew J McGirtAlfredo Quiñones-Hinojosa
Jan 27, 2009·International Journal of Radiation Oncology, Biology, Physics·Philip H GutinLauren E Abrey
Feb 12, 2009·Molecular Cancer Therapeutics·Gary L GalliaGregory J Riggins
Jun 27, 2009·Expert Opinion on Investigational Drugs·Cory AdamsonDarell D Bigner
Feb 18, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wolfgang WickRoger Stupp
Mar 27, 2010·International Journal of Radiation Oncology, Biology, Physics·Mackenzie C McGeeAndrew M Davidoff
Apr 6, 2011·Journal of the National Comprehensive Cancer Network : JNCCN·David A ReardonHenry S Friedman
May 3, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·James J VredenburghHenry S Friedman
May 24, 2011·Clinical Medicine Insights. Oncology·Marc C Chamberlain
Nov 1, 2011·Journal of Neurosurgery·Ashwatha NarayanaMichael L Gruber

❮ Previous
Next ❯

Citations

Mar 13, 2016·Drug Discovery Today·Farshad RamazaniRobbert J Kok
Mar 27, 2016·Journal of Controlled Release : Official Journal of the Controlled Release Society·Antonella MangravitiHenry Brem
Jan 13, 2015·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·T XieX Luo
Mar 10, 2015·Neuro-oncology·Scott D WaitAnthony L Asher
Nov 5, 2016·Journal of Controlled Release : Official Journal of the Controlled Release Society·C BastiancichF Danhier
Jan 28, 2017·Molecular Pharmaceutics·Edgardo Rivera-Delgado, Horst A von Recum
Nov 26, 2016·Advanced Healthcare Materials·Sue Anne Chew, Serena Danti
Jan 13, 2018·Journal of Neuro-oncology·Gregory D ArnoneAnkit I Mehta
Feb 16, 2019·Journal of Biomedical Materials Research. Part B, Applied Biomaterials·Daniel A Rodriguez de AndaSue Anne Chew
Feb 28, 2015·Surgical Neurology International·Antonella MangravitiHenry Brem
Oct 6, 2020·Journal of Oncology·Amir R AfshariAmirhossein Sahebkar
Dec 17, 2020·Pharmaceutics·Jessica I GriffithWilliam F Elmquist
Sep 9, 2020·Journal of Controlled Release : Official Journal of the Controlled Release Society·Gi Doo ChaDae-Hyeong Kim
Aug 31, 2021·Advanced Drug Delivery Reviews·Chiara BastiancichRuman Rahman

❮ Previous
Next ❯

Methods Mentioned

BETA
xenografts

Software Mentioned

GraphPadPrism
GraphPad

Related Concepts

Related Feeds

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.